Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Svicher V, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. doi: 10.1128/AAC.01067-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124665 Free PMC article.
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. Aquaro S, et al. J Antimicrob Chemother. 2006 Oct;58(4):714-22. doi: 10.1093/jac/dkl306. Epub 2006 Aug 5. J Antimicrob Chemother. 2006. PMID: 16891628
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure.
Svicher V, Aquaro S, D'Arrigo R, Artese A, Dimonte S, Alcaro S, Santoro MM, Di Perri G, Caputo SL, Bellagamba R, Zaccarelli M, Visco-Comandini U, Antinori A, Narciso P, Ceccherini-Silberstein F, Perno CF. Svicher V, et al. J Infect Dis. 2008 May 15;197(10):1408-18. doi: 10.1086/587693. J Infect Dis. 2008. PMID: 18419549
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
Ceccherini-Silberstein F, Malet I, Fabeni L, Dimonte S, Svicher V, D'Arrigo R, Artese A, Costa G, Bono S, Alcaro S, Monforte Ad, Katlama C, Calvez V, Antinori A, Marcelin AG, Perno CF. Ceccherini-Silberstein F, et al. J Antimicrob Chemother. 2010 Nov;65(11):2305-18. doi: 10.1093/jac/dkq326. Epub 2010 Sep 3. J Antimicrob Chemother. 2010. PMID: 20817922
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Dynamics of NRTI resistance mutations during therapy interruption.
Trignetti M, Sing T, Svicher V, Santoro MM, Forbici F, D'arrigo R, Bellocchi MC, Santoro M, Marconi P, Zaccarelli M, Trotta MP, Bellagamba R, Narciso P, Antinori A, Lengauer T, Perno CF, Ceccherini-Silberstein F. Trignetti M, et al. AIDS Res Hum Retroviruses. 2009 Jan;25(1):57-64. doi: 10.1089/aid.2008.0159. AIDS Res Hum Retroviruses. 2009. PMID: 19182921
71 results